We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


BioFocus DPI launches ADME/PK service and software platform

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "BioFocus DPI launches ADME/PK service and software platform"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

BioFocus DPI, a leading provider of gene-to-preclinical discovery services, announces the launch of ADME/PK Laboratory and the StarDropTM software platform.

ADME/PK Laboratory is the new name for the expanded BioFocus DPI ADMEnsa Laboratory service. In addition to providing high-quality in vitro services backed by expert consultancy, ADME/PK Laboratory extends beyond early ADME to incorporate in vivo pharmacokinetics and bioanalysis. These capabilities provide key information to interpret a new drug’s potential for achieving the required ADME profile in man.

The new StarDrop (structure-activity relationships for drug optimization) software suite is an upgrade to BioFocus DPI’s ADMEnsa Interactive package. StarDrop has been expanded beyond the prediction of ADME properties to include interactive data visualization and compound modeling for effective decision making. Its unique compound prioritization capabilities integrate in silico predictions with in vitro and in vivo data to enable the design, prioritization and selection of compounds with an optimal balance of properties at every stage of drug discovery.

“With the launch of ADME/PK Laboratory we are pleased to offer customers a full range of in vitro and in vivo services that can be tailored to meet the specific needs of a discovery program,” said Matthew Segall, BioFocus DPI’s Senior Director ADMET. “Through StarDrop, we aim to facilitate effective decision making by creating an intuitive environment for the design and identification of compounds that are likely to succeed in downstream drug discovery and development.”